OBJECTIVE: We examined the association between surgical hospital volume and both overall survival (OS) and disease-free survival (DFS) using data obtained from the international CRITICS (ChemoRadiotherapy after Induction chemotherapy In Cancer of the Stomach) trial. SUMMARY BACKGROUND DATA: In the CRITICS trial, patients with resectable gastric cancer were randomized to receive preoperative chemotherapy followed by adequate gastrectomy and either chemotherapy or chemoradiotherapy. METHODS:Patients in the CRITICS trial who underwent a gastrectomy with curative intent in a Dutch hospital were included in the analysis. The annual number of gastric cancer surgeries performed at the participating hospitals was obtained from the Netherlands Cancer Registry; the hospitals were then classified as low-volume (1-20 surgeries/year) or high-volume (≥21 surgeries/year) and matched with the CRITICS trial data. Univariate and multivariate analyses were then performed to evaluate the hazard ratio (HR) between hospital volume and both OS and DFS. RESULTS:From 2007 through 2015, 788 patients were included in the CRITICS trial. Among these 788 patients, 494 were eligible for our study; the median follow-up was 5.0 years. Five-year OS was 59.2% and 46.1% in the high-volume and low-volume hospitals, respectively. Multivariate analysis revealed that undergoing surgery in a high-volume hospital was associated with higher OS [HR = 0.69, 95% confidence interval (CI) = 0.50-0.94, P = 0.020] and DFS (HR = 0.73, 95% CI: 0.54-0.99, P = 0.040). CONCLUSIONS: In the CRITICS trial, hospitals with a high annual volume of gastric cancer surgery were associated with higher overall and DFS. These findings emphasize the value of centralizing gastric cancer surgeries in the Western world.
RCT Entities:
OBJECTIVE: We examined the association between surgical hospital volume and both overall survival (OS) and disease-free survival (DFS) using data obtained from the international CRITICS (ChemoRadiotherapy after Induction chemotherapy In Cancer of the Stomach) trial. SUMMARY BACKGROUND DATA: In the CRITICS trial, patients with resectable gastric cancer were randomized to receive preoperative chemotherapy followed by adequate gastrectomy and either chemotherapy or chemoradiotherapy. METHODS:Patients in the CRITICS trial who underwent a gastrectomy with curative intent in a Dutch hospital were included in the analysis. The annual number of gastric cancer surgeries performed at the participating hospitals was obtained from the Netherlands Cancer Registry; the hospitals were then classified as low-volume (1-20 surgeries/year) or high-volume (≥21 surgeries/year) and matched with the CRITICS trial data. Univariate and multivariate analyses were then performed to evaluate the hazard ratio (HR) between hospital volume and both OS and DFS. RESULTS: From 2007 through 2015, 788 patients were included in the CRITICS trial. Among these 788 patients, 494 were eligible for our study; the median follow-up was 5.0 years. Five-year OS was 59.2% and 46.1% in the high-volume and low-volume hospitals, respectively. Multivariate analysis revealed that undergoing surgery in a high-volume hospital was associated with higher OS [HR = 0.69, 95% confidence interval (CI) = 0.50-0.94, P = 0.020] and DFS (HR = 0.73, 95% CI: 0.54-0.99, P = 0.040). CONCLUSIONS: In the CRITICS trial, hospitals with a high annual volume of gastric cancer surgery were associated with higher overall and DFS. These findings emphasize the value of centralizing gastric cancer surgeries in the Western world.
Authors: Joshua Tseng; James P Miller; Jeffrey Johnson; Kevin Waters; Alexandra Gangi; Jun Gong; Miguel Burch Journal: J Gastrointest Oncol Date: 2021-08
Authors: Sarah R Kaslow; Zhongyang Ma; Leena Hani; Katherine Prendergast; Gerardo Vitiello; Ann Y Lee; Russell S Berman; Judith D Goldberg; Camilo Correa-Gallego Journal: J Surg Oncol Date: 2022-04-26 Impact factor: 2.885
Authors: Joon Y Park; Arjun Verma; Zachary K Tran; Michael A Mederos; Peyman Benharash; Mark Girgis Journal: Ann Surg Oncol Date: 2022-01-07 Impact factor: 5.344
Authors: Lei Huang; Lina Jansen; Rob H A Verhoeven; Jelle P Ruurda; Liesbet Van Eycken; Harlinde De Schutter; Jan Johansson; Mats Lindblad; Tom B Johannesen; Vesna Zadnik; Tina Žagar; Sjoerd M Lagarde; Cornelis J H van de Velde; Petra Schrotz-King; Hermann Brenner Journal: Cancer Commun (Lond) Date: 2022-06-06
Authors: Giovanni Maria Garbarino; Gianluca Costa; Giovanni Guglielmo Laracca; Giorgio Castagnola; Paolo Mercantini; Massimiliano Di Paola; Simone Vita; Luigi Masoni Journal: Langenbecks Arch Surg Date: 2020-08-04 Impact factor: 3.445